SEARCH

SEARCH BY CITATION

References

  • 1
    Markham A, Goa KL. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs. 1997;54:299311.
  • 2
    Wagstaff AJ. Valsartan/hydrochlorothiazide: a review of its use in the management of hypertension. Drugs. 2006;66:18811901.
  • 3
    Plosker GL, Robinson DM. Amlodipine/valsartan: fixed-dose combination in hypertension. Drugs. 2008;68:373381.
  • 4
    Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:16671675.
  • 5
    Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:18931906.
  • 6
    Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:20222031.
  • 7
    Mochizuki S, Dahlof B, Shimizu M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet. 2007;369:14311439.
  • 8
    Sinaiko AR, Gomez-Marin O, Prineas RJ. Prevalence of “significant” hypertension in junior high school-aged children: the Children and Adolescent Blood Pressure Program. J Pediatr. 1989;114:664669.
  • 9
    Sorof JM, Lai D, Turner J, et al. Overweight, ethnicity, and the prevalence of hypertension in school-aged children. Pediatrics. 2004;113:475482.
  • 10
    Lurbe E, Torro I, Alvarez V, et al. Prevalence, persistence, and clinical significance of masked hypertension in youth. Hypertension. 2005;45:493498.
  • 11
    Hansen ML, Gunn PW, Kaelber DC. Underdiagnosis of hypertension in children and adolescents. JAMA. 2007;298:874879.
  • 12
    Flynn JT, Meyers KE, Neto JP, et al. Efficacy and safety of the angiotensin receptor blocker valsartan in children with hypertension aged 1 to 5 years. Hypertension. 2008;52:222228.
  • 13
    Wells T, Blumer J, Zeyes KE, et al. Effectiveness and safety of valsartan in children aged 6 to 16 years with hypertension. J Clin Hypertens (Greenwich). 2011;13:357365.
  • 14
    Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA. 2006;295:15491555.
  • 15
    Shields M. Overweight and obesity among children and youth. Health Rep. 2006;17:2742.
  • 16
    Rosner B, Prineas R, Daniels SR, et al. Blood pressure differences between blacks and whites in relation to body size among US children and adolescents. Am J Epidemiol. 2000;151:10071019.
  • 17
    Invitti C, Gilardini L, Pontiggia B, et al. Prevalence and concomitance of high blood pressure in Italian obese children. J Hypertens. 2005;23:16051606.
  • 18
    Cook S, Weitzman M, Auinger P, et al. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med. 2003;157:821827.
  • 19
    Weiss R, Dziura J, Burgert TS, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med. 2004;350:23622374.
  • 20
    Ford ES, Li C, Zhao G, et al. Prevalence of the metabolic syndrome among U.S. adolescents using the definition from the International Diabetes Federation. Diabetes Care. 2008;31:587589.
  • 21
    National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114(2 suppl):555576.
  • 22
    Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:12061252.
  • 23
    Grassi G, Seravalle G, Dell’Oro R, et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens. 2003;21:17611769.
  • 24
    Fogari R, Derosa G, Zoppi A, et al. Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. Hypertens Res. 2005;28:209214.
  • 25
    Negro R, Formoso G, Hassan H. The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients. J Endocrinol Invest. 2006;29:957961.
  • 26
    Fogari R, Preti P, Zoppi A, et al. Effect of valsartan addition to amlodipine on insulin sensitivity in overweight-obese hypertensive patients. Intern Med. 2008;47:18511857.
  • 27
    Yamana A, Arita M, Furuta M, et al. The angiotensin II receptor blocker telmisartan improves insulin resistance and has beneficial effects in hypertensive patients with type 2 diabetes and poor glycemic control. Diabetes Res Clin Pract. 2008;82:127131.
  • 28
    Weir MR, Crikelair N, Levy D, et al. Evaluation of the dose response with valsartan and valsartan/hydrochlorothiazide in patients with essential hypertension. J Clin Hypertens (Greenwich). 2007;9:103112.
  • 29
    Everett BM, Glynn RJ, Danielson E, et al. Combination therapy versus monotherapy as initial treatment for stage 2 hypertension: a prespecified subgroup analysis of a community-based, randomized, open-label trial. Clin Ther. 2008;30:661672.
  • 30
    Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch Intern Med. 2004;164:722732.
  • 31
    Nuesch R, Schroeder K, Dieterle T, et al. Relation between insufficient response to antihypertensive treatment and poor compliance with treatment: a prospective case–control study. BMJ. 2001;323:142146.
  • 32
    Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther. 1998;20:671681.
  • 33
    Conlin PR, Gerth WC, Fox J, et al. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes. Clin Ther. 2001;23:19992010.
  • 34
    Marentette MA, Gerth WC, Billings DK, et al. Antihypertensive persistence and drug class. Can J Cardiol. 2002;18:649656.
  • 35
    Wallenius SH, Vainio KK, Korhonen MJ, et al. Self-initiated modification of hypertension treatment in response to perceived problems. Ann Pharmacother. 1995;29:12131217.
  • 36
    Lip GY, Beevers DG. Doctors, nurses, pharmacists and patients – the Rational Evaluation and Choice in Hypertension (REACH) survey of hypertension care delivery. Blood Press. 1997;6(suppl 1):610.
  • 37
    Gregoire JP, Moisan J, Guibert R, et al. Tolerability of antihypertensive drugs in a community-based setting. Clin Ther. 2001;23:715726.
  • 38
    Munger MA, Van Tassell BW, LaFleur J. Medication nonadherence: an unrecognized cardiovascular risk factor. MedGenMed. 2007;9:58.
  • 39
    Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol. 1995;75:793795.
  • 40
    Waldmeier F, Flesch G, Muller P, et al. Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica. 1997;27:5971.
  • 41
    Wellington K, Faulds DM. Valsartan/hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension. Drugs. 2002;62:19832005.
  • 42
    Brook RD, Bard RL, Kehrer C, et al. Valsartan improves insulin sensitivity without altering vascular function in healthy overweight adults without the metabolic syndrome. Metab Syndr Relat Disord. 2007;5:255261.
  • 43
    Jordan J, Engeli S, Boschmann M, et al. Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients. J Hypertens. 2005;23:23132318.
  • 44
    Top C, Cingözbay BY, Terekeci H, et al. The effects of valsartan on insulin sensitivity in patients with primary hypertension. J Int Med Res. 2002;30:1520.
  • 45
    Rehman A, Rahman AR, Rasool AH. Effect of angiotensin II on pulse wave velocity in humans is mediated through angiotensin II type 1 (AT(1)) receptors. J Hum Hypertens. 2002;16:261266.
  • 46
    Klingbeil AU, John S, Schneider MP, et al. Effect of AT1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens. 2003;16:123128.
  • 47
    Shrikhande G, Khaodhiar L, Scali S, et al. Valsartan improves resting skin blood flow in type 2 diabetic patients and reduces poly(adenosine diphosphate-ribose) polymerase activation. J Vasc Surg. 2006;43:760770.
  • 48
    Duprez DA, Florea ND, Jones K, et al. Beneficial effects of valsartan in asymptomatic individuals with vascular or cardiac abnormalities: the DETECTIV Pilot Study. J Am Coll Cardiol. 2007;50:835839.
  • 49
    Karalliedde J, Smith A, DeAngelis L, et al. Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering. Hypertension. 2008;51:16171623.
  • 50
    Okura T, Watanabe S, Kurata M, et al. Long-term effects of angiotensin II receptor blockade with valsartan on carotid arterial stiffness and hemodynamic alterations in patients with essential hypertension. Clin Exp Hypertens. 2008;30:415422.
  • 51
    Dandona P, Kumar V, Aljada A, et al. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metab. 2003;88:44964501.
  • 52
    Manabe S, Okura T, Watanabe S, et al. Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension. J Cardiovasc Pharmacol. 2005;46:735739.
  • 53
    Ridker PM, Danielson E, Rifai N, et al. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension. 2006;48:7379.
  • 54
    Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002;106:672678.
  • 55
    Hollenberg NK, Parving HH, Viberti G, et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens. 2007;25:19211926.
  • 56
    Uzu T, Sawaguchi M, Maegawa H, et al. Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART). Diabetes Care. 2007;30:15811583.